172477-99-5 Usage
General Description
(1-Benzyl-piperidin-3-yl)-methyl-carbamic acid tert-butyl ester, also known as Boc-Piperidine, is a chemical compound with the molecular formula C17H26N2O2. It is commonly used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and materials. Boc-Piperidine is also used as a protecting group for amines in organic synthesis. (1-BENZYL-PIPERIDIN-3-YL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER is a white to off-white solid that is soluble in organic solvents such as ethanol and methanol. It is important to handle Boc-Piperidine with caution, as it is considered to be a hazardous chemical and can cause irritation to the skin, eyes, and respiratory system if not handled properly.
Check Digit Verification of cas no
The CAS Registry Mumber 172477-99-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,2,4,7 and 7 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 172477-99:
(8*1)+(7*7)+(6*2)+(5*4)+(4*7)+(3*7)+(2*9)+(1*9)=165
165 % 10 = 5
So 172477-99-5 is a valid CAS Registry Number.
172477-99-5Relevant articles and documents
SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1
-
, (2018/01/20)
The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
